+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 60Years
All Genders
ID07282821

Study of Bempedoic Acid Compared to Placebo for Adults with Autosomal Dominant Polycystic Kidney Disease

Led by Kenneth Hallows · Updated on 2026-09-29

120

Participants Needed

3

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

Autosomal dominant polycystic kidney disease ADPKD is the most common inherited kidney disease, causing cysts that impair kidney function and often lead to end-stage kidney disease by age 60. Current treatment options are limited, with Tolvaptan being the only FDA-approved drug, but it has side effects like frequent urination, thirst, and possible liver injury. Researchers are studying bempedoic acid BA, a drug approved for high cholesterol, which may target key cellular processes involved in ADPKD and help slow disease progression. This phase 2 clinical trial will randomly assign 120 adults aged 18 to 60 with rapidly progressing ADPKD to receive either bempedoic acid 180 mg daily or a placebo for two years. Participants may be on or off a stable dose of Tolvaptan. The study will be conducted at three specialized centers, with patients monitored regularly through lab tests, questionnaires, and MRI scans to measure kidney and liver volumes and fat content. Researchers will also explore urinary biomarkers related to disease severity and response to treatment. Participants will have in-person visits at baseline, 3, 6, 12, 18, and 24 months to collect urine samples, complete quality of life surveys, and undergo lab tests. MRI scans will be performed at the start, one year, and two years to assess organ volumes. Safety and tolerability will be closely monitored through adverse event tracking and pill counts. The study aims to evaluate if bempedoic acid is safe and tolerable and to gather early data on its effects on kidney function and quality of life over the two-year treatment period.

CONDITIONS

Brief Title

Bempedoic Acid Therapy for Polycystic Kidney Disease

Research Team

C

Charalett Diggs, RN, MSN

K

Kenneth R Hallows, MD, PhD, FASN

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here